REFIXIA is a brand name for the medication nonacog beta pegol, which is a recombinant coagulation factor IX product. It is specifically designed for the treatment and management of hemophilia B, a genetic disorder that impairs blood clotting due to a deficiency or dysfunction of factor IX. REFIXIA works by replacing the missing or defective factor IX, thereby helping the blood to clot normally and preventing prolonged bleeding episodes. This medication is used in both adults and children, and it can be administered for prophylaxis to prevent bleeding episodes, on-demand treatment of bleeding, and perioperative management during surgery. REFIXIA is administered through intravenous injection, and its extended half-life allows for less frequent dosing compared to traditional factor IX products, offering a significant improvement in the quality of life for individuals with hemophilia B.